SLC5A2 and diabetes mellitus: Among the therapeutic options for the treatment of hyperglycemia, thiazolidinediones (TZDs) represent a significant breakthrough in the history of diabetes management, preceding the discovery of DPP-4 inhibitors, SGLT2 inhibitors, and glucagon-like peptide-1 receptor (GLP-1R) agonists.